← All stocks

Avalo Therapeutics, Inc.

AVTX Mostly scheduled

CIK 0001534120 #2500 in the set updated 21 Sep 2026

Bought (12 mo)

$0.00

out of their own pocket, the only kind of buying there is

Sold (12 mo)

$8.50M

$565.64K on a plan · $7.88M straight out of an exercise

Sold at will

$52.01K

1 of 43 sales

Net

−$8.50M

−$52.01K against sales at will

By person

11 insiders · 43 transactions

Insider

Role

Bought

Sold

Net

Holding

Worth

Change

Sullivan Christopher Ryan

Chief Financial Officer

—

$3.72M (17) scheduled

−$3.72M

39,900

$651.71K

+3,322%

Doyle Mittie

Chief Medical Officer

—

$2.98M (17) scheduled

−$2.98M

51,776

$845.68K

+399.1%

VARKI PAUL

Chief Legal Officer

—

$1.51M (5) scheduled

−$1.51M

32,576

$532.08K

+214.0%

Goldman Jonathan

Director

—

$162.94K (2) scheduled

−$162.94K

3,166

$51.71K

—

Chan Mitchell

Director

—

$72.46K (1) scheduled

−$72.46K

3,166

$51.71K

—

Riley Jennifer

Chief Strategy Officer

—

$52.01K (1)

−$52.01K

37,041

$605.01K

+451.1%

NEIL GARRY ARTHUR

Chief Executive Officer

—

190,314

$3.11M

+317,090%

KAPLAN GILLA

Director

—

6,333

$103.44K

—

Truex Samantha

Director

—

6,333

$103.44K

—

KANTOFF AARON

Director

—

6,333

$103.44K

—

Almenoff June Sherie

Director

—

4,167

$68.06K

—

No percentages here. This company's share count has moved by a factor of 5.2 over the window, from 10,393,954 to 53,629,989 shares. A split, a merger or a large issue changes what the company is, and a holding measured at one point in that run is not a fraction of it at another.

Individual transactions

Nothing of that kind in this period.

What was left out

Form 4 filings counted 66

Amendments (4/A) skipped 0

Filings about a different issuer 0

Unreadable filings 0

Joint filings 0

Sales on a Rule 10b5-1 plan 7

Sales straight out of an exercise 35

Sales at will 1

Transactions with no price 0

Shares from compensation/vesting 777,657

History held since 3 Oct 2016